| 2.1 0.01 (0.48%) | 04-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.73 | 1-year : | 3.19 |
| Resists | First : | 2.33 | Second : | 2.73 |
| Pivot price | 1.68  |
|||
| Supports | First : | 1.51 | Second : | 1 |
| MAs | MA(5) : | 2.08 |
MA(20) : | 1.57 |
| MA(100) : | 1.93 |
MA(250) : | 1.8 |
|
| MACD | MACD : | 0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 87.5 |
D(3) : | 89.3 |
| RSI | RSI(14): 66.1 |
|||
| 52-week | High : | 3.05 | Low : | 0.87 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ MIST ] has closed below upper band by 24.3%. Bollinger Bands are 158.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 17 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.17 - 2.18 | 2.18 - 2.19 |
| Low: | 2.02 - 2.04 | 2.04 - 2.05 |
| Close: | 2.08 - 2.1 | 2.1 - 2.12 |
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
Thu, 16 Apr 2026
[144] Milestone Pharmaceuticals Inc. SEC Filing - Stock Titan
Tue, 07 Apr 2026
Milestone will stream its Needham healthcare conference talk on Apr. 13 - Stock Titan
Thu, 02 Apr 2026
Three new hires get 123,000 Milestone stock options under Nasdaq rule - Stock Titan
Tue, 31 Mar 2026
Express Scripts adds new PSVT nasal spray to national formularies - Stock Titan
Mon, 23 Mar 2026
Milestone Pharmaceuticals Inc. (MIST) GC reports 400,000-share stock option - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 118 (M) |
| Held by Insiders | 1.406e+007 (%) |
| Held by Institutions | 2.4 (%) |
| Shares Short | 7,470 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -6.203e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 116.2 % |
| Return on Equity (ttm) | -41.1 % |
| Qtrly Rev. Growth | 1.55e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -425.28 |
| EBITDA (p.s.) | 2.87037e+006 |
| Qtrly Earnings Growth | -0.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -49 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 3.33 |
| Dividend | 0 |
| Forward Dividend | 8.76e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|